Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RIGL vs RGNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RIGL Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 10–0 Matrix Metrics)

RIGL Overall Winner 6-Pillar Tally: RIGL 4 – 2 RGNX Matrix Metrics: RIGL 10 – 0 RGNX

As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RIGL carries a Unified Composite Score of 59.9/100 (HOLD) at $43.74 (9.3x Forward P/E, 26.3% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin).

  • Technical & Structure Timing Caution: RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RIGL vs RGNX
RIGL NASDAQ Head-to-Head Winner
Rigel Pharmaceuticals Inc. (New)
Pharmaceutical Preparations
$43.74
-1.61% 1D
Market Cap $860.3M
TTM Revenue $288M
Forward P/E 9.3x
Beta / 30D Vol 1.06β · 74% Vol
Unified Composite Score
59.9 / 100 HOLD
Tech 48.0 Fund 58.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.6 · SMA20: $47.42 · SMA50: $47.34
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.45
-2.49% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.82β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63

6-Pillar Scorecard Institutional Category Breakdown (RIGL 4 – 2 RGNX)

Columns: Metric · RIGL · RGNX
1. Valuation Multiples RIGL
Forward P/E 9.3x N/M
Trailing P/E 2.8x N/M
PEG Ratio N/M 0.26x
EV / Revenue 2.9x 3.1x
2. Growth & Scale RIGL
Revenue Growth (YoY) +16.5% -69.2%
Earnings Growth (YoY) -55.5% +0.0%
TTM Revenue (USD) $288M $154M
Market Cap $860.3M $500.9M
3. Profitability & Quality RIGL
Gross Margin 70.7% -64.5%
Operating Margin 26.3% -120.4%
Net Profit Margin 106.6% -113.9%
Return on Equity (ROE) 109.2% -113.2%
4. Balance Sheet & Cash Flow RIGL
Cash Generation (TTM) $19M -$155M
Cash Flow Margin 6.7% -100.6%
Net Cash / Leverage $39M Net Cash $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RGNX
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 61.2% (4th %ile) 349.6% (52nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 44.4% of Rev ($128M) 55.9% of Rev ($86M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RIGL (10) vs RGNX (0)
Institutional Metric RIGL RGNX Criterion Row Edge
Market Capitalization
Scale
$860.3M $500.9M Larger Scale RIGL
Trailing P/E Ratio
Valuation
2.8x N/M Lower Multiple RIGL
Forward P/E Ratio
Valuation
9.3x N/M Lower Multiple RIGL
Revenue Growth (YoY)
Growth
+16.5% -69.2% Higher Growth RIGL
Operating Margin (TTM)
Profitability
26.3% -120.4% Higher Margin RIGL
Net Profit Margin
Profitability
106.6% -113.9% Higher Margin RIGL
Return on Equity (ROE)
Capital Efficiency
109.2% -113.2% Higher ROE RIGL
52-Week Range Position
Momentum
68% ($25–$53) 19% ($5–$16) Stronger Trend RIGL
Beta / 30D Volatility
Risk Regime
1.06β · 74% Vol 1.82β · 76% Vol Lower Realized Risk RIGL
Unified Institutional Score
Composite Signal
59.9 / 100 (HOLD) 45.3 / 100 (HOLD) Higher Composite RIGL
Trailing 12M Revenue (USD)
Operating Scale
$288M $154M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.7% -64.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.9x EV/Rev 0.26x PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$19M ($39M Net Cash) -$155M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RGNX +12.42 pp
RIGL: -4.84% · RGNX: +7.58%
3M Horizon RIGL +32.99 pp
RIGL: +0.29% · RGNX: -32.7%
6M Horizon RIGL +21.04 pp
RIGL: +52.9% · RGNX: +31.86%
1Y Horizon RIGL +45.69 pp
RIGL: +9.69% · RGNX: -36.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RIGL Revenue RGNX Revenue RIGL Op. Margin RGNX Op. Margin Margin Leader
FY2018 $40M $220M -163.3% 40.3% RGNX
FY2019 $60M $40M -116.5% -422.9% RIGL
FY2020 $110M $150M -26.7% -77.1% RIGL
FY2021 $150M $470M -8.4% 34.0% RGNX
FY2022 $120M $110M -46.2% -233.2% RIGL
FY2023 $120M $90M -17.5% -297.1% RIGL
FY2024 $180M $80M 13.5% -280.0% RIGL
FY2025 $290M $170M 42.6% -94.6% RIGL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RIGL CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 61.2%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RIGL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RIGL Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $860.3M market capitalization and 26.3% operating margin.
OpEx & R&D Reinvestment 44.4% of Rev ($128M)
90D Engineering Disclosures 0 Published
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published

Investor FAQ RIGL vs RGNX Key Questions & Quantitative Answers

As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RIGL carries a Unified Composite Score of 59.9/100 (HOLD) at $43.74 (9.3x Forward P/E, 26.3% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin). Technical & Structure Timing Caution: RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RIGL leads the Growth & Scale pillar: RIGL posts +16.5% YoY revenue growth and -55.5% YoY earnings growth on $288M TTM revenue (70.7% gross margin, 26.3% operating margin), compared with RGNX at -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RIGL cumulative revenue shifted +625.0% while RGNX shifted -22.7%. In operating R&D and SG&A reinvestment, RIGL deploys 44.4% of Rev ($128M) (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($86M) (0 disclosures) for RGNX.

RIGL screens cheaper on headline valuation multiples. RIGL trades at 9.3x Forward P/E, 2.8x Trailing P/E, N/M PEG, and 2.9x EV/Revenue (6.7% FCF margin), whereas RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RIGL (109.2% ROE) versus RGNX (-113.2% ROE) capital efficiency.

In options market volatility and institutional positioning, RIGL carries 61.2% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.06β · 74% Vol realized risk). By comparison, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.